Exposure–safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease

BACKGROUND: Nintedanib reduces the rate of decline in forced vital capacity in patients with idiopathic pulmonary fibrosis (IPF), other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype and systemic sclerosis-associated ILD (SSc-ILD). The recommended dose of nintedanib...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmid, Ulrike, Weber, Benjamin, Sarr, Celine, Freiwald, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293560/
https://www.ncbi.nlm.nih.gov/pubmed/34289823
http://dx.doi.org/10.1186/s12890-021-01598-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293560/
https://www.ncbi.nlm.nih.gov/pubmed/34289823
http://dx.doi.org/10.1186/s12890-021-01598-0

Ejemplares similares